Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies.
October 19, 2026 - 14:56
By Pharos Investment Advisors Comments are Off
Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved